Y-mAbs Therapeutics (YMAB)

• Market cap: $371M
• 1 day: -3.38%
• 5 days: -24.31%
• 1 month: -21.44%
• 3 months: -39.69%
• 6 months: -29.53%
• Year to date: 20.52%
• 1 year: 35.74%
• 5 years: -73.92%
• 10 years: -65.50%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Employees: 100

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

11,160% more call options, than puts

Call options by funds: $563K | Put options by funds: $5K

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

24% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 29

14% more capital invested

Capital invested by funds: $297M [Q2] → $339M (+$42M) [Q3]

11% more funds holding

Funds holding: 95 [Q2] → 105 (+10) [Q3]

1.79% more ownership

Funds ownership: 55.96% [Q2] → 57.76% (+1.79%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 105% upside
• Avg. target: $20 142% upside
• High target: $23 178% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Brookline Capital Kemp Dolliver 25% 1-year accuracy 1 / 4 met price target	105% upside $17	Buy Initiated	5 Dec 2024
Oppenheimer Jeff Jones 24% 1-year accuracy 10 / 41 met price target	178% upside $23	Outperform Initiated	18 Nov 2024